Amneal Biosciences Launches First Product / by Scott A.

Generic fosphenytoin sodium injection in stock and now available

Bridgewater, New Jersey (USA), October 6, 2016 – Amneal Biosciences (www.amnealbiosciences.com), a wholly-owned subsidiary of Amneal Pharmaceuticals LLC, has launched its first commercial product.

Fosphenytoin sodium injection, USP, is available in 100 mg PE* / 2 mL (50 mg PE / mL) strength in a 25-count pack of single-dose vials and 500 mg PE / 10 mL (50 mg PE / mL) strength in a 10-pack of single-dose vials.  The product began shipping in August.

“We at Amneal Biosciences are very excited about the launch of our first product and its ability to address industry shortages in hospitals, clinics, and acute care facilities. Fosphenytoin, along with our other upcoming launches, is fully aligned with the strategic direction of the company,” said Amneal Biosciences president Charles Lucarelli,

According to July 2016 IMS market data, annual (MAT) U.S. sales of the brand Cerebyx®and its generic equivalents totaled $38 million.

Amneal Biosciences is dedicated to the commercialization of high-barrier-to-entry generic and specialty pharmaceuticals such as injectables, oncologics, anti-infectives and support care for healthcare providers and patients of all ages.  The company’s expertise and focus on the unique needs and logistics of this market segment ensure the same level of quality and service for healthcare institutions and professionals that Amneal delivers to its retail customers.

To view full prescribing information for fosphenytoin sodium injection click or visit http://www.amneal.com/wp-content/uploads/2016/09/FosphenytoinSodiumInj-PI.pdf.

*PE = phenytoin sodium equivalents